Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Carregando...
Citações na Scopus
520
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC CLINICAL ONCOLOGY
Autores
OLSEN, Elise A.
WHITTAKER, Sean
KIM, Youn H.
DUVIC, Madeleine
PRINCE, H. Miles
LESSIN, Stuart R.
WOOD, Gary S.
WILLEMZE, Rein
DEMIERRE, Marie-France
PIMPINELLI, Nicola
Citação
JOURNAL OF CLINICAL ONCOLOGY, v.29, n.18, p.2598-2607, 2011
Resumo
Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS. J Clin Oncol 29:2598-2607. (C) 2011 by American Society of Clinical Oncology
Palavras-chave
Referências
- Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
- Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502
- SAUSVILLE EA, 1988, ANN INTERN MED, V109, P372
- Kim YH, 2003, ARCH DERMATOL, V139, P857, DOI 10.1001/archderm.139.7.857
- BUNN PA, 1979, CANCER TREAT REP, V63, P725
- Harmon CB, 1996, J AM ACAD DERMATOL, V35, P404, DOI 10.1016/S0190-9622(96)90605-2
- LUTZNER M, 1975, ANN INTERN MED, V83, P534
- SCHECHTER GP, 1987, BLOOD, V69, P841
- Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
- Vonderheid EC, 2002, J AM ACAD DERMATOL, V46, P95, DOI 10.1067/mjd.2002.118538
- Olsen E, 2001, J CLIN ONCOL, V19, P376
- Dummer R, 1999, ARCH DERMATOL RES, V291, P307, DOI 10.1007/s004030050414
- Cheson BD, 1996, BLOOD, V87, P4990
- Chren MM, 2001, J CUTAN MED SURG, V5, P105, DOI 10.1007/s102270000010
- Chren MM, 1996, J INVEST DERMATOL, V107, P707, DOI 10.1111/1523-1747.ep12365600
- Pimpinelli N, 2005, J AM ACAD DERMATOL, V53, P1053, DOI 10.1016/j.jaad.2005.08.057
- Bogen SA, 1996, AM J CLIN PATHOL, V106, P739
- Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
- Demierre MF, 2005, ARCH DERMATOL, V141, P325
- Duvic M, 2001, ARCH DERMATOL, V137, P581
- SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4
- Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749
- Jones D, 2001, AM J CLIN PATHOL, V115, P885
- Stevens SR, 2002, ARCH DERMATOL, V138, P42, DOI 10.1001/archderm.138.1.42
- Bernengo MG, 2001, BRIT J DERMATOL, V144, P125, DOI 10.1046/j.1365-2133.2001.04014.x
- BOROWITZ MJ, 1993, LEUKEMIA, V7, P859
- Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149
- Duncan K, 1998, J INVEST DERMATOL, V110, P645
- EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603
- Gobbi PG, 2002, HAEMATOLOGICA, V87, P1151
- GOROCHOV G, 1995, J INVEST DERMATOL, V105, P56, DOI 10.1111/1523-1747.ep12312560
- Hopper KD, 1996, AM J ROENTGENOL, V167, P851
- KUKEL S, 1994, CLIN EXP IMMUNOL, V98, P163
- LEWIS E, 1982, J COMPUT ASSIST TOMO, V6, P792, DOI 10.1097/00004728-198208000-00025
- Reinhold U, 1997, J CLIN IMMUNOL, V17, P265, DOI 10.1023/A:1027318530127
- RIEGER E, 1989, J CUTAN PATHOL, V16, P7, DOI 10.1111/j.1600-0560.1989.tb00002.x
- Steinhoff M, 2009, LEUKEMIA RES, V33, P88, DOI 10.1016/j.leukres.2008.06.025
- Vonderheid EC, 2001, J INVEST DERMATOL, V117, P654, DOI 10.1046/j.1523-1747.2001.01456.x
- Vonderheid EC, 2006, LEUKEMIA LYMPHOMA, V47, P1841, DOI 10.1080/10428190600709655
- Vonderheid EC, 2003, HEMATOL ONCOL CLIN N, V17, P1367, DOI 10.1016/S0889-8588(03)00120-5
- ZACKHEIM HS, 1995, HEMATOL ONCOL CLIN N, V9, P1021